NCT07162181 2026-04-17
Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers
Eli Lilly and Company
Phase 2 Active not recruiting
Clinical Trials
3 trialsNCT06522386 2026-04-16
GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05677919 2026-02-12
Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia
Mayo Clinic
Phase 2 Active not recruiting